Pharmacogenetics of Solid Tumors: Directed Therapy in Breast, Lung, and Colorectal Cancer

Snozek, Christine L.H.; O’Kane, Dennis J.; Algeciras‐Schimnich, Alicia

doi:10.2353/jmoldx.2009.090003

Cited by 11 publications

(6 citation statements)

References 80 publications

(80 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In cancer patients, the hereditary polymorphism of enzymes are accountable for signaling paths and biotransformation of drug due to which adverse effects happen upon administration of chemotherapeutic agents [47]. This is also recognized that the chemotherapeutic agents are not selective for just cancer cells and they influence cell lines conveying higher growth and imitation rates.…”

Section: Discussionmentioning

confidence: 99%

Effects of Chemotherapy in Breast Cancer Patients

Anjum

Razvi²,

Saeed³

2017

Natl. j. health sci.

View full text Add to dashboard Cite

Introduction: A descriptive, non-interventional study was conducted from April 2011 to September 2013, at KIRAN hospital, Karachi among n = 811 female breast cancer patients to assess the effects of chemotherapeutic agents that were employed for the treatment of breast cancer. The assessment was done so as to see the variation in response of the patients towards the drugs used specifically the adverse effects that have to be combated during therapy.Methodology: During 3-6 months, a follow up was done to collect data for ADEs (Adverse Drug Events) that occurred among patients after therapy. The SPSS version 16.0 was used for statistical analysis of the data. The adverse events that occurred due to adjuvant chemotherapy including severity, preventability and causality were evaluated using three International scales i.e. Modified Schumock and Thornton scale, modified Hartwig's and Siegal's scale and Naranjo's algorithm. Results and Discussion:Majority of the patients received 6 cycles of FAC therapy (5-fluorouracil, Adriamycin/doxorubicin, cyclophosphamide) and showed good response. The assessment of ADRs using different scales revealed hair loss, nausea, vomiting, anemia and neutropenia as the non-preventable definite effects that were experienced by the patients. Mild to moderate diarrhea/constipation was probably preventable and hence doubtful. Moderately probable effects included mucositis and mouth ulcers whereas possible effects included fever and chills. Conclusion:Through the right use of medicines, the mild effect of headache and pain could be certainly preventable. Hence chemotherapeutic agents must be chosen for each patient on individual basis to prevent or lessen the toxic effects rendered to them and be useful in the disease course.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of Chemotherapy in Breast Cancer Patients

Anjum

Razvi²,

Saeed³

2017

Natl. j. health sci.

View full text Add to dashboard Cite

show abstract

“…Uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) is involved in metabolizing Irinotecan's more potent metabolite SN-38 to inactive SN-38-glucuronide. For patients with the reduced activity UGT1A alleles, treatment with Irinotecan may result in increased toxicity [117] . Hence, prospective genotyping of the UGT1A locus would facilitate optimizing the chemotherapy for individual patients.…”

Section: Current Challenges and Future Directionsmentioning

confidence: 99%

“…However, a recent study by Uzilov et al has shown that using integrative genomic approaches in the clinical setting for colorectal, breast, and medullary thyroid carcinomas has led to significantly enhanced personalized therapeutic strategies for clinicians [114] . Thus, we believe that integrating genomic findings into clinics and hospitals will provide more effective patient stratification and guide therapeutic options Although targeted therapy is a hallmark in the treatment of blood cancers, such as leukemia, there has been a wealth of successful pharmacogenomic discoveries in solid tumors as well [115][116][117] . These include Tamoxifen in treating ER+ breast cancer and EGFR-directed therapies for lung cancer patients [117] .…”

Section: Current Challenges and Future Directionsmentioning

confidence: 99%

“…Thus, we believe that integrating genomic findings into clinics and hospitals will provide more effective patient stratification and guide therapeutic options Although targeted therapy is a hallmark in the treatment of blood cancers, such as leukemia, there has been a wealth of successful pharmacogenomic discoveries in solid tumors as well [115][116][117] . These include Tamoxifen in treating ER+ breast cancer and EGFR-directed therapies for lung cancer patients [117] . In addition, the patient's genotype information may be used to modify therapy, such as in the case of Irinotecan in metastatic colorectal patients.…”

Section: Current Challenges and Future Directionsmentioning

confidence: 99%

See 1 more Smart Citation

The advancements of genomics and data integration in sarcoma research

et al. 2017

View full text Add to dashboard Cite

Abstract:In the age of big data, genomics and clinical research have reached a crossroads. A wealth of data is being generated, but it is becoming increasingly complicated to analyze these data to extract meaningful results. The ability to understand biological systems holistically has unprecedented potential to transform how cancers are treated. Recent major advances leading biomedical research towards "systems medicine" have been fueled by high-throughput platforms, such as microarrays and next-generation sequencing, which can capture vast amounts of data in different genomic spaces. Unfortunately, because of high dimensionality and complex relationships among these data, inferring comprehensive and useful biological models has proven computationally and statistically challenging. However, novel bioinformatic methods for data integration of cancer genomic datasets have been developed. In this review, we will describe the applications of various genomic approaches in sarcoma research and introduce bioinformatic methods for data integration. With the continuing evolution of technological and bioinformatic methodologies, the application of big data within clinics and hospitals will ultimately result in significant improvements on how cancers are detected and treated.Keywords: omics; genomics; sarcomas; sequencing; microarray; data integration; bioinformatics; big data

show abstract

“…In CRC and lung cancers, somatic mutations in the EGFR and downstream signaling molecules have been associated with the therapeutic outcome of EGFR-directed therapies. Current advances in single gene-UGT1A1, CYP2D6, EGFR, and K-ras-or multigene analysis contribute to optimizing breast, colorectal, and lung cancer therapy, highlighting how pharmacogenetics has helped in personalized decision-making for patient management (Snozek et al 2009 ).…”

Section: Pharmacogenetics Of Cancer Chemotherapymentioning

confidence: 99%

Personalized Cancer Therapy

Jain

2013

Applications of Biotechnology in Oncology

View full text Add to dashboard Cite

Pharmacogenetics of Solid Tumors: Directed Therapy in Breast, Lung, and Colorectal Cancer

Cited by 11 publications

References 80 publications

Effects of Chemotherapy in Breast Cancer Patients

Effects of Chemotherapy in Breast Cancer Patients

The advancements of genomics and data integration in sarcoma research

Personalized Cancer Therapy

Contact Info

Product

Resources

About